Osimertinib, a third-generation EGFR-TKI that selectively inhibits the EGFR T790M mutation, has been a successful treatment for patients with T790M-positive NSCLC who have acquired resistance to prior-line EGFR-TKIs (45). This evidence concerns the gene EGFR and non-small cell lung carcinoma.